Skip to HighlightsSkip to Recommendations
Pursuant to a congressional request, GAO assessed the medical component of the Department of Defense's (DOD) Biological Defense Research Program, operated by the Army's Medical Research and Development Command.
Recommendations for Executive Action
|Department of the Army||1. The Secretary of the Army should direct the Medical Research and Development Command to review all ongoing medical research projects to determine whether they address validated warfare threat agents and discontinue all projects that do not.|
|Department of the Army||2. The Secretary of the Army should direct the Medical Research and Development Command to arrange for independent reviews of all proposed research projects by officials from the Armed Forces Medical Intelligence Center and the Academy of Health Sciences to ensure that all future projects address validated warfare agents, and report the results of each review to the Army Surgeon General.|
|Department of the Army||3. The Army should amend its regulations to require the systematic coordination of its medical biological research projects with those of other federal research databases.|
|Department of the Army||4. The Secretary of the Army should direct the Medical Research and Development Command to discontinue development of all products that do not address validated threats.|